PR: Mount Sinai Announces the Formation of CastleVax Inc., a Clinical-Stage Infectious Diseases Company Targeting Pandemic Threats and Diseases of Unmet Medical Need
The Mount Sinai Health System in New York, NY, has launched CastleVax, Inc. (“CastleVax”), a clinical-stage vaccine research and development company. CastleVax is devoted to the commercial development of the Newcastle disease virus (NDV) vaccine platform technology originally developed in the laboratories of Peter Palese, PhD; Adolfo García-Sastre, PhD; and Florian Krammer, PhD, at the Icahn School of Medicine at Mount Sinai.
A Phase 1/2 Randomized, Placebo-controlled (phase 1) and Active- controlled (phase 2), Observer-blind Trial to Assess the Safety and Immunogenicity of COVIVAC Vaccine…
Phase 2 trial results of NDV-HXP-S in Vietnam via the Institute of Vaccines and Medical Biologicals (IVAC). Results show higher concentration of neutralizing Ab in NDV-HXP-S group compared to AstraZeneca group. Phase 3 in planning.